Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population - Perez-Iglesias, Rocio; Mata, Ignacio; Pelayo-Teran, Jose M.; Amado, Jose A.; Garcia-Unzueta, Maria T.; Berja, Ana; Martinez-Garcia, Obdulia; Vazquez-Barquero, Jose L.; Crespo-Facorro, Benedicto (Schizophrenia research, 2009)
Keywords: Adolescent; Adult; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Antipsychotics; Benzodiazepines - adverse effects; Benzodiazepines - therapeutic use; Biological and medical sciences; Blood Glucose - metabolism; Cholesterol; Cholesterol - blood; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Female; First episode psychosis; Follow-Up Studies; Glucose; Haloperidol; Haloperidol - adverse effects; Haloperidol - therapeutic use; Humans; Insulin; Insulin - blood; Insulin Resistance - physiology; Long-term; Male; Medical sciences; Middle Aged; Neuropharmacology; Olanzapine; Pharmacology. Drug treatments; Prospective Studies; Psychiatry; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Risk Factors; Risperidone; Risperidone - adverse effects; Risperidone - therapeutic use; Schizophrenia - blood; Schizophrenia - drug therapy; Spain; Triglycerides; Triglycerides - blood; Weight Gain - drug effects; Young Adult; First episode psychosis; Antipsychotics; Olanzapine; Long-term; Triglycerides; Glucose; Haloperidol; Risperidone; Insulin; Cholesterol; Pancreatic hormone; Atypical antipsychotic; Neuroleptic; Psychotropic; Pharmacotherapy; Lipids; Serotonine receptor; Psychosis; Benzisoxazole derivatives; Human; Dopamine antagonist; Serotonin antagonist; Butyrophenone derivatives; Triglyceride; Long term; Thienobenzodiazepine derivatives; D2 Dopamine receptor; Treatment; First episode